Bronchiectasis Drugs Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Rising Diagnosis of Bronchiectasis Through High-Resolution CT and Microbiology

Respiratory specialists increasingly identified bronchiectasis when assessing patients with persistent asthma or COPD symptoms using high-resolution CT. The WHO identified chronic respiratory disease as a key setting for earlier diagnosis and coordinated respiratory care. As a result, specialist consultations for obstructive lung disease became an important pathway to bronchiectasis diagnosis and subsequent treatment. A 2026 European Respiratory Society review reported rising prevalence across multiple cohorts as diagnostic capacity improved. The European Medicines Agency granted PRIME support to brensocatib, reflecting the unmet need in NCFB and a clearer regulatory pathway for disease-specific therapies.^{[1]Jing Liu et al., “Prevalence of Bronchiectasis in Adults: A Meta-Analysis,” BMC Public Health, doi.org.} The bronchiectasis drugs market could expand as more diagnosed patients moved from general respiratory care into specialist treatment pathways.

Recurrent Exacerbations and Long-Term Antibiotic Utilization

A 2025 randomized trial found that dual and triple inhaled bronchodilator regimens reduced exacerbations among bronchiectasis patients with airflow obstruction. The findings strengthened the clinical rationale for long-acting combination therapies in patients with coexisting obstructive respiratory disease. This supported demand for products such as GSK’s Trelegy Ellipta and AstraZeneca’s Breztri Aerosphere. The 2025 European Respiratory Society guideline advised against routine inhaled corticosteroid use in patients without asthma or COPD while maintaining its role for eligible patients. The guidance focused treatment on appropriate patient populations and supported recurring prescription demand in the bronchiectasis drugs market.^{[2]World Health Organization, “Global Scientific Panel on Chronic Respiratory Diseases: Background Paper,” World Health Organization, who.int.}

Precision Stratification by Neutrophilic and Eosinophilic Phenotypes

Blood eosinophil counts became increasingly relevant in identifying bronchiectasis patients who could benefit from inhaled corticosteroids. EMBARC registry findings published in 2025 showed fewer exacerbations and hospitalizations among corticosteroid users with elevated eosinophil levels than among comparable patients with normal levels. This evidence supported phenotype-based treatment decisions rather than broad empirical use. It also provided manufacturers with a clearer basis for developing therapies for patients with eosinophilic disease characteristics. Sanofi’s itepekimab program introduced a biologic approach that differed from DPP-1 inhibition. The bronchiectasis drugs market could develop separate treatment pathways for neutrophilic and eosinophilic disease if future clinical evidence supported distinct labels.

Home-Based Nebulization and Digital Adherence Monitoring

Digital respiratory tools helped patients track medication-use patterns and receive adherence reminders outside clinical settings. Aptar Digital Health received FDA 510(k) clearance in 2025 for HeroTracker Sense, a Bluetooth-enabled sensor for pressurized metered-dose inhalers. These tools supported care teams in distinguishing poor adherence from inadequate drug response. Oral brensocatib reduced dependence on inhaler training because patients took it once daily. Insmed’s inLighten program combined financial support with services designed to support treatment use. The bronchiectasis drugs market increasingly extended beyond medicines to include patient support and home-based monitoring.

Device Burden and Adherence Challenges in Chronic Nebulized Therapy

Correct inhaler technique remains essential for patients to achieve expected treatment benefits. Uneven access to telehealth support and specialist guidance creates gaps in respiratory care. Incorrect inhaler use may make patients appear unresponsive despite appropriate therapy, prompting unnecessary medication changes. The European Respiratory Society guideline requires careful patient selection for inhaled corticosteroids, which remains challenging without regular respiratory monitoring. These gaps limit treatment outcomes and slow the adoption of higher-value inhaled regimens in the bronchiectasis drugs market.

Antimicrobial Resistance and Diminishing Antibiotic Durability

Safety considerations remain critical when selecting long-term anti-inflammatory and bronchodilator therapies. The European Respiratory Society guideline limits routine inhaled corticosteroid use because benefit-risk profiles vary across patient groups. Brensocatib requires continued safety monitoring after approval. In the ASPEN study, alanine aminotransferase elevations greater than three times the upper limit of normal occurred in 0.9% of patients receiving 25 mg, while skin cancer occurred in 1.9% of patients, compared with 1.1% for placebo. These findings may make prescribers cautious about transitioning patients to newer treatments, while payer authorization and post-marketing surveillance requirements may delay market access.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Bronchiectasis Drugs Market Segment Analysis

Antibiotics accounted for 38.59% of the bronchiectasis drugs market in 2025. Recent clinical evidence continues to strengthen the antibiotics subsegment in the bronchiectasis market. A July 2024 meta-analysis published in CHEST confirmed that inhaled antibiotics significantly reduce exacerbation frequency and sputum bacterial load in adults with bronchiectasis, supporting greater adoption of long-term suppressive antibiotic therapy. Additionally, the January 2024 ERASE trial demonstrated the effectiveness of inhaled tobramycin, with or without oral ciprofloxacin, for eradicating Pseudomonas aeruginosa, validating combination antibiotic approaches for chronic infection management. Together, these findings are expected to boost physician confidence, support guideline-based use, and drive growth of the antibiotics subsegment in bronchiectasis treatment.

DPP-1 and Cathepsin C inhibitors are projected to grow at a CAGR of 24.25% through 2031, making them the fastest-growing drug class. Recent clinical advancements have strengthened the emerging DPP-1 and cathepsin C inhibitor subsegments in the bronchiectasis drugs market. The Phase III ASPEN trial demonstrated that the DPP-1 inhibitor brensocatib reduced exacerbations in bronchiectasis patients, providing a strong foundation for disease-modifying therapy. Additionally, the Phase II AIRLEAF trial reported positive dose-finding results for the cathepsin C inhibitor BI 1291583, supporting pipeline expansion and increasing the future therapeutic options available for bronchiectasis management.

Oral route of administration accounted for 50.09% of the bronchiectasis drugs market in 2025, and it is also expected to be the fastest-growing segment with a projected CAGR of 17.97% thorugh 2031. Brensocatib introduced an oral, once-daily treatment option designed specifically for non-cystic fibrosis bronchiectasis (NCFB). The broader DPP-1 inhibitor class may create additional oral treatment options following the first commercial entry. A 2025 meta-analysis found that DPP-1 inhibitors reduced exacerbation frequency by 27%, with a risk ratio of 0.73 and moderate-certainty evidence. Oral therapies may support homecare and specialty clinic models by reducing device-handling requirements and enabling treatment outside hospitals.

Oral azithromycin remained an important treatment option for preventing pulmonary exacerbations in bronchiectasis. A 2025 systematic review and meta-analysis involving 562 patients across six randomized controlled trials confirmed its efficacy in reducing exacerbation frequency, reinforcing the clinical value of oral antibiotic therapy and supporting continued growth of the oral-route segment in the market.

Adults accounted for 57.45% of bronchiectasis drug revenue in 2025, driven by the higher diagnosed prevalence of bronchiectasis among adults due to cumulative respiratory exposures, comorbidities, and structural lung damage. Demand within this segment was further supported by the growing adoption of disease-modifying therapies. The ASPEN protocol and baseline characteristics study published in 2024 established a robust clinical foundation for evaluating brensocatib in adults with non-cystic fibrosis bronchiectasis, reinforcing confidence in emerging targeted treatments and supporting continued growth of the adult segment.

The older adults are forecasted to expand at a CAGR of 16.30% through 2031, as bronchiectasis prevalence increases with age and improved diagnosis. Growth in this segment is supported by expanding clinical focus on age-specific disease management. A 2025 review published in Clinics in Geriatric Medicine highlighted the need for tailored diagnostic and treatment approaches for older adults with bronchiectasis, addressing the impact of comorbidities, polypharmacy, and functional limitations. This increasing emphasis on geriatric-focused care is expected to encourage earlier diagnosis, more consistent treatment initiation, and greater utilization of bronchiectasis therapies among aging patient populations.

Retail and community pharmacies accounted for 42.87% of distribution channel revenue in 2025, supported by their extensive prescription dispensing networks and accessibility for patients requiring long-term respiratory therapies. Continued pharmacy consolidation, including CVS Health’s acquisition of former Rite Aid and Bartell Drugs stores and prescription files, helped preserve medication access for patients receiving chronic bronchiectasis treatments such as antibiotics and mucolytic therapies, reinforcing the segment’s leadership position.

Specialty pharmacies are projected to grow at a CAGR of 17.30% through 2031, driven by their expanding role in dispensing innovative bronchiectasis therapies. The launch of brensocatib through a limited-distribution network involving Amber Specialty Pharmacy, PANTHERx Rare Pharmacy, and later Maxor Specialty Pharmacy established a specialized commercial infrastructure for disease-modifying bronchiectasis treatment. This growing reliance on specialty pharmacy channels for advanced therapies is expected to support strong growth of the segment over the coming years.

Geography Analysis

North America Bronchiectasis Drugs Market

North America held a 44.75% share of the bronchiectasis drugs market in 2025. The United States has the largest commercially addressable diagnosed NCFB population and the most developed specialty reimbursement infrastructure. Insmed estimated that the United States had 500,000 diagnosed NCFB patients, with half potentially meeting the clinical eligibility criteria for brensocatib. Brinsupri had an annual list price of USD 88,000 per patient in the United States, supporting higher revenue per treated patient. Canada and Mexico added demand for bronchodilators and corticosteroids, although access to disease-specific therapies developed more slowly.

Europe Bronchiectasis Drugs Market

Europe was the second-largest regional market for bronchiectasis drugs. The European Commission authorized Brinsupri in November 2025 for patients aged 12 years and older with at least two exacerbations in the preceding 12 months. Pricing and reimbursement negotiations across member states can delay broad commercial access. The EMA estimated that 400,000 to 3 million people in the European Union had NCFB, highlighting uneven diagnosis and disease recording. Germany, the United Kingdom, and France remained key early-access markets, while the United Kingdom authorized Brinsupri in February 2026 for eligible patients aged 12 years and older.

APAC, MEA and South America Bronchiectasis Drugs Market

Asia-Pacific is forecast to grow at a CAGR of 17.25% through 2031, the highest regional rate in the bronchiectasis drugs market. China reported a prevalence of 1,200 per 100,000 people aged 40 years and older, and the BE-China registry improved visibility into the country’s patient population. Insmed expected a Japanese regulatory decision for brensocatib in the second half of 2026. South Korea reported a prevalence of 886 per 100,000 adults, indicating significant treatment demand, while tuberculosis-related lung damage remained a major cause of bronchiectasis in India. The Middle East and Africa and South America held a combined share below 15% in 2025, where tender procurement and access constraints favored generic respiratory therapies.